$2.6T
Total marketcap
$169.2B
Total volume
BTC 49.99%     ETH 15.81%
Dominance

Incyte INCY Stock

57.34 USD {{ price }} -1.764603% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
12.87B USD
LOW - HIGH [24H]
57.3 - 58.75 USD
VOLUME [24H]
1.7M USD
{{ volume }}
P/E Ratio
21.63
Earnings per share
2.65 USD

Incyte Price Chart

Incyte INCY Financial and Trading Overview

Incyte stock price 57.34 USD
Previous Close 61.44 USD
Open 61.37 USD
Bid 0 USD x 800
Ask 0 USD x 900
Day's Range 61.21 - 62.65 USD
52 Week Range 60.61 - 86.29 USD
Volume 3.18M USD
Avg. Volume 1.82M USD
Market Cap 13.96B USD
Beta (5Y Monthly) 0.715845
PE Ratio (TTM) 43.458332
EPS (TTM) 2.65 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 82.24 USD

INCY Valuation Measures

Enterprise Value 10.63B USD
Trailing P/E 43.458332
Forward P/E 13.371796
PEG Ratio (5 yr expected) 1.22
Price/Sales (ttm) 4.0232143
Price/Book (mrq) 3.1280615
Enterprise Value/Revenue 3.065
Enterprise Value/EBITDA 18.472

Trading Information

Incyte Stock Price History

Beta (5Y Monthly) 0.715845
52-Week Change -12.19%
S&P500 52-Week Change 20.43%
52 Week High 86.29 USD
52 Week Low 60.61 USD
50-Day Moving Average 67.56 USD
200-Day Moving Average 73.89 USD

INCY Share Statistics

Avg. Volume (3 month) 1.82M USD
Avg. Daily Volume (10-Days) 2.26M USD
Shares Outstanding 223.09M
Float 185.69M
Short Ratio 3.67
% Held by Insiders 1.53%
% Held by Institutions 96.51%
Shares Short 6.87M
Short % of Float 3.69%
Short % of Shares Outstanding 3.08%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 9.34%
Operating Margin (ttm) 14.46%
Gross Margin 47.86%
EBITDA Margin 16.58%

Management Effectiveness

Return on Assets (ttm) 5.78%
Return on Equity (ttm) 7.79%

Income Statement

Revenue (ttm) 3.47B USD
Revenue Per Share (ttm) 15.6 USD
Quarterly Revenue Growth (yoy) 10.29%
Gross Profit (ttm) 1.59B USD
EBITDA 575.7M USD
Net Income Avi to Common (ttm) 324.37M USD
Diluted EPS (ttm) 1.44
Quarterly Earnings Growth (yoy) -42.89%

Balance Sheet

Total Cash (mrq) 3.11B USD
Total Cash Per Share (mrq) 13.95 USD
Total Debt (mrq) 40.24M USD
Total Debt/Equity (mrq) 0.9 USD
Current Ratio (mrq) 3.948
Book Value Per Share (mrq) 20.006

Cash Flow Statement

Operating Cash Flow (ttm) 648.6M USD
Levered Free Cash Flow (ttm) 522.97M USD

Profile of Incyte

Country United States
State DE
City Wilmington
Address 1801 Augustine Cut-Off
ZIP 19803
Phone 302 498 6700
Website https://www.incyte.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2324

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Q&A For Incyte Stock

What is a current INCY stock price?

Incyte INCY stock price today per share is 57.34 USD.

How to purchase Incyte stock?

You can buy INCY shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Incyte?

The stock symbol or ticker of Incyte is INCY.

Which industry does the Incyte company belong to?

The Incyte industry is Biotechnology.

How many shares does Incyte have in circulation?

The max supply of Incyte shares is 224.53M.

What is Incyte Price to Earnings Ratio (PE Ratio)?

Incyte PE Ratio is 21.63773500 now.

What was Incyte earnings per share over the trailing 12 months (TTM)?

Incyte EPS is 2.65 USD over the trailing 12 months.

Which sector does the Incyte company belong to?

The Incyte sector is Healthcare.

Incyte INCY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
S&P 500 (Yahoo.com) GSPC 5149.42 USD
+0.63
2.4B USD 5145.47 USD 5175.6 USD 2.4B USD
S&P 500 INDEX SPX 5149.42 USD
+0.63
2.39B USD 5145.47 USD 5175.6 USD 2.39B USD
Dow Jones U.S. Biotechnology In DJUSBT 2844.59 USD
+0.08
79.29M USD 2839.63 USD 2860.51 USD 79.29M USD
NASDAQ Composite Total Return I XCMP 19565.06 USD
+0.82
19553.78 USD 19740.18 USD
NASDAQ Q 50 NXTQ 737.55 USD
-0.27
737.3 USD 745.3 USD
Nasdaq US Price Setters Index NQPRCE 2590.23 USD
+0.35
2589.18 USD 2601.12 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
The Capital Strength Net Total NQCAPSTN 3590.32 USD
+0.24
3587.81 USD 3605.83 USD
Nasdaq Next Generation 100 Inde NGX 1138.09 USD
-0.13
1137.73 USD 1146.36 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Biotechnology Total Retu XNBI 4654.3 USD
-0.65
4652.69 USD 4696.7 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD